Viatris(VTRS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company reported total revenues of $14.3 billion, representing approximately 2% growth compared to 2024, excluding the impact of the India pack [5][24] - Adjusted EBITDA for 2025 was $4.2 billion, with adjusted EPS of $2.35 per share and free cash flow of $2.2 billion, excluding transaction-related costs [24][30] - The company prioritized capital return with over $1 billion returned to shareholders through dividends and share repurchases [7][24] Business Line Data and Key Metrics Changes - The fourth quarter of 2025 saw total revenues of $3.7 billion, up 1% year-over-year, driven by strong commercial performance across key regions [23] - Growth in Greater China was supported by demand in the cardiovascular portfolio, while Europe and emerging markets benefited from the breadth and competitive strength of the portfolio [23][27] - The company expects new product revenues of $450-550 million in 2026, contributing to strong segment performance [26] Market Data and Key Metrics Changes - In developed markets, net sales are expected to grow by 2% versus 2025, with Europe anticipated to grow by 4% year-over-year [26][27] - Emerging markets are expected to grow by 6% year-over-year, driven by expansion in key growth markets such as Turkey, Mexico, India, and Brazil [27] - In Greater China, the company expects to deliver 3% year-over-year growth, primarily driven by cardiovascular products [29] Company Strategy and Development Direction - The company aims to drive its base business by executing successful launches and evolving its generics portfolio towards more profitable products [8][9] - The strategic review is expected to deliver approximately $650 million in gross cost savings over three years, with plans to reinvest up to $250 million into growth areas [7][25] - The company is focused on modernizing for sustainable growth by strengthening technology, data, and talent capabilities [9][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering a period of long-term sustainable growth beginning in 2026, with strong execution anticipated [5][10] - The company expects robust cash flow in 2026, providing financial flexibility for balanced capital allocation [11][32] - Management highlighted the importance of upcoming product launches and regulatory decisions as key drivers for future performance [10][12] Other Important Information - A fire occurred at the company's oral solid dose manufacturing facility in Nashik, India, temporarily suspending operations, with expectations to resume in April [30] - The company is preparing for regulatory decisions for several product candidates, including EFFEXOR and pitolisant in Japan, and fast-acting meloxicam in the U.S. [10][15] Q&A Session Summary Question: Path to mid-single-digit revenue growth - Management indicated that the path to mid-single-digit revenue growth involves a growing base business and upcoming product launches, with confidence in achieving this over the next few years [37][40] Question: Timing of $400 million savings from strategic review - The savings are expected to be phased over three years, with approximately 30% in 2026, 30% in 2027, and 40% in 2028 [38][42] Question: Breakdown of $650 million savings - About 50% of the savings will come from headcount reductions, with the other half from COGS efficiencies and inventory management [44][46] Question: India recovery impact on EBITDA guidance - Management assumes a little less than 1% recovery from India in the top line, with no material impact expected on 2026 guidance [44][49] Question: Restructuring charges versus net savings - The company estimates that the one-time costs necessary to achieve savings will be about 1 times the gross savings, with around $250 million expected this year [52][54] Question: Fast-acting meloxicam market focus - The initial focus for fast-acting meloxicam will be on post-operative and operative acute pain management, targeting specialty physicians [58][60] Question: Regulatory pricing challenges in Japan - Japan faces mandatory price decreases on LOE products, impacting revenue and EBITDA, but management is optimistic about future growth with new assets [62][64]